A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma-Reference-Cited by-同舟云学术

A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma

Published:2020-06 Issue:3 Volume:157 Page:585-592
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Duska L.R.,Petroni G.R.,Varhegyi N.,Brown J.,Jelovac D.,Moore K.N.,McGuire W.P.,Darus C.,Barroilhet L.M.,Secord A.A.

Funder

Novartis

University of Virginia

GSK

Merck

PTC Therapeutics

Lilly

Genentech

Roche

Clovis

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference24 articles.

1. Cancer statistics;Siegel;CA Canc. J. Clin.,2018

2. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients;Wagner;Br. J. Canc.,2012

3. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer;Aghajanian;Gynecol. Oncol.,2015

4. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial;Pujade-Lauraine;J. Clin. Oncol.,2014

5. Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer;D’Agostino;Gynecol. Oncol.,2003

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of VEGFR inhibitors for recurrent ovarian cancer: a systematic review;Future Oncology;2024-08-12

2. New hopes and promises in the treatment of ovarian cancer focusing on targeted treatment—a narrative review;Frontiers in Pharmacology;2024-06-14

3. Efficacy and safety of anti-angiogenic drug monotherapy and combination therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials;Frontiers in Pharmacology;2024-05-27

4. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer;Cochrane Database of Systematic Reviews;2023-04-18

5. Analysis of Efficacy-To-Safety Ratio of Angiogenesis-Inhibitors Based Therapies in Ovarian Cancer: A Systematic Review and Meta-Analysis;Diagnostics;2023-03-09